Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

Cataldo Patruno; Luca Stingeni; Katharina Hansel; Silvia Mariel Ferrucci; Simona Tavecchio; Gabriella Fabbrocini; Steven Paul Nisticò; Caterina Foti; Serena De Prezzo; Maddalena Napolitano

doi:10.1111/dth.13290

Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

Dermatol Ther. 2020 May;33(3):e13290. doi: 10.1111/dth.13290. Epub 2020 Mar 11.

Affiliations

¹ Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
² Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy.
³ Dermatology Section, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
⁴ Department of Physiopathology and Transplantation, University of Milan, Milan, Italy.
⁵ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
⁶ Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, Bari, Italy.
⁷ Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.

PMID: 32125741
DOI: 10.1111/dth.13290

Abstract

Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.

Keywords: adult atopic dermatitis; dupilumab; nummular eczema; phenotype.

Publication types

Multicenter Study

MeSH terms

Adolescent
Adult
Antibodies, Monoclonal, Humanized
Dermatitis, Atopic* / diagnosis
Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Phenotype
Severity of Illness Index

Substances

Antibodies, Monoclonal, Humanized
dupilumab